Vincent Ossipow
Gründer bei OMEGA ALPHA SPAC
Vermögen: 2 Mio $ am 30.04.2024
Ursprung des Netzwerks ersten Grades von Vincent Ossipow
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 30 | |
Omega Fund Management LLC
 Omega Fund Management LLC Investment ManagersFinance Omega Fund Management Ltd. (OFM) is the wholly-owned private equity firm founded by Dr. Otello Stampacchia in 2004. The firm is headquartered in the US.
24
| Private Company | Investment Managers | 24 |
| Public Company | Packaged Software | 23 | |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.
19
| Holding Company | Biotechnology | 19 |
| Public Company | Pharmaceuticals: Major | 18 | |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
FoRx Therapeutics AG
 FoRx Therapeutics AG Pharmaceuticals: MajorHealth Technology FoRx Therapeutics AG operates as a biotechnology company developing a new generation of cancer drugs focusing on novel deoxyribonucleic acid (DNA) Replication Stress pathways activated in cancer. The firm also provides research and development services. The company was founded by Thanos Halazonetis and Sotirios K. Sotiriou in 2019 and is headquartered in Basel, Switzerland.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Aerium Therapeutics, Inc.
 Aerium Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Aerium Therapeutics, Inc. is an American biotechnology company that focuses on epidemic and pandemic preparedness. The company is based in Lausanne and has operations in the United States. The company's mission is to discover and develop antibodies and small molecule antivirals against SARS-CoV-2 and other epidemic and pandemic threats. Aerium Therapeutics has a team of world-class scientists and biotechnology veterans, as well as experienced investors. Aerium's lead assets are monoclonal antibodies that show broad activity against important variants of concern (VOCs) of SARS-CoV-2, including Omicron and its subvariants. The company plans to expand its pipeline to antiviral therapeutics in late 2022 and will broaden its focus to other epidemic and pandemic threats in the future. The CEO of the company is Rajeev Venkayya.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
| Private Company | Financial Conglomerates | 7 | |
| Public Company | Biotechnology | 5 | |
NeoMed S.à.r.l.
3
| Subsidiary | Investment Managers | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Vincent Ossipow
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Harvard Business School | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin Masters Business Admin Masters Business Admin Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Undergraduate Degree | |
Nuvation Bio Operating Co., Inc.
 Nuvation Bio Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Nuvation Bio Operating Co., Inc. engages in the provision of biotechnology company developing proprietary therapies focuse on oncology. It portfolio includes Seven Novel and Mechanistically Distinct Oncology Programs, Each with Multiple Drug Development Candidates. The company was founded by David Hung in 2018 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
| Erasmus University Rotterdam | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin Doctorate Degree | |
| University of Lund | College/University | Undergraduate Degree Masters Business Admin Undergraduate Degree Graduate Degree | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director of Finance/CFO Director/Board Member Chief Executive Officer Director/Board Member | |
| The Trustees of Columbia University in The City of New York | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin Graduate Degree | |
| 4SC AG | Biotechnology | Chairman Founder Corporate Officer/Principal Corporate Officer/Principal | |
| BIOGEN INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal | |
| University of Cambridge | College/University | Undergraduate Degree Masters Business Admin Graduate Degree | |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Director of Finance/CFO Private Equity Investor | |
| University of Geneva | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Sales & Marketing Sales & Marketing | |
| AFFIMED N.V. | Biotechnology | Chairman Director/Board Member Director of Finance/CFO | |
| University of California, Berkeley | College/University | Corporate Officer/Principal Undergraduate Degree Graduate Degree | |
| University of Oxford | College/University | Masters Business Admin Undergraduate Degree Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Missouri | College/University | Masters Business Admin Undergraduate Degree | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| Immunic Research GmbH | Chief Executive Officer Chief Executive Officer | ||
| University of California San Diego | College/University | Corporate Officer/Principal Graduate Degree | |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Executive Officer Comptroller/Controller/Auditor | |
| TRANSLATE BIO, INC. | Biotechnology | Chairman Director/Board Member | |
Cure Ventures Management LP
 Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Biotechnology | Founder Chief Tech/Sci/R&D Officer | |
Cell Medica Switzerland AG
 Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Founder Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| MEDIVIR AB | Pharmaceuticals: Major | Chairman Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Corporate Officer/Principal | |
Vectura GmbH
 Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Medical Specialties | Director/Board Member Director/Board Member | |
Affimed NV Niederlassung Deutschland
 Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| Massachusetts Institute of Technology | College/University | Undergraduate Degree Corporate Officer/Principal | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Director of Finance/CFO | |
| BLUEBIRD BIO, INC. | Biotechnology | Director/Board Member Chairman | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Director of Finance/CFO | |
| BEAM THERAPEUTICS INC. | Biotechnology | Director/Board Member Director/Board Member | |
| ASTRIA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Fund+
 Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor Private Equity Investor | |
| Boston University | College/University | Undergraduate Degree Graduate Degree |
Statistik
International
| Vereinigte Staaten | 30 |
| Deutschland | 6 |
| Schweiz | 5 |
| Vereinigtes Königreich | 5 |
| Belgien | 4 |
Sektoral
| Health Technology | 27 |
| Consumer Services | 14 |
| Finance | 8 |
| Commercial Services | 4 |
Operativ
| Director/Board Member | 602 |
| Corporate Officer/Principal | 185 |
| Independent Dir/Board Member | 139 |
| Chairman | 101 |
| Chief Executive Officer | 73 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Jane M. Birgitta Stymne Göransson | 50 |
| Michael Powell | 48 |
| Tamar Howson | 41 |
| Stephen Knight | 39 |
| John Maraganore | 38 |
| Otello Stampacchia | 37 |
| Marijn Dekkers | 35 |
| Jörg Neermann | 34 |
| Daniel Lynch | 32 |
| Nanna Liebach Lüneborg | 29 |
| Gerhard Ries | 27 |
| Claudio Nessi | 25 |
| Thomas O. Hecht | 24 |
| Bernd Seizinger | 23 |
| Dina Chaya | 23 |
- Börse
- Insiders
- Vincent Ossipow
- Unternehmensverbindungen
